Our Story

The initial idea for Deep Lens came together when the founders, Dave, Simon and TJ, realized that Dave`s digital pathology inventions from his days as head of innovation at Nationwide Children`s Hospital could form the basis for a completely rethought approach to clinical trial recruitment.

In 2017 Dave, the pathology innovator, pitched Simon, the serial analytics and AI entrepreneur and TJ, the cancer genetics PhD and strategy consultant, on the idea of a new company. From the inception of the idea to today, our team has been true to form, growing with major biopharma, provider and strategic partners to take on the status quo and provide a truly groundbreaking approach to clinical trial recruitment so that patients can get the therapies they want and deserve.

85% of clinical trials fail to meet planned timelines
11% of study sites won`t enroll a single patient
1 in 33 Adult cancer patients participate in clinical trials

Deep Lens accelerates clinical trial enrollment
Precision medicine changed the game in oncology clinical trials. Biomarkers can confidently identify eligible patients, but result in competition for patients at care sites.

By focusing on community oncology, Deep Lens is helping to open new doors for clinical trial managers. The result is as much as a 300% increase in accrual rates. Learn more about how we accelerate clinical trials below.

Community Oncology Focused
The Deep Lens Unity Network is the fastest growing community oncology network in the country. Check out all the benefits of membership here.

Experienced Clinical Staff
Dedicated clinical research coordinators work with care teams to pre-screen eligible patients. Spend more time on patient care and less on chart review.

AI-Powered Patient Identification
VIPER is Deep Lens’ AI-powered platform that identifies patients based on trial criteria. Easy to use dashboards ensure your enrollment goals stay on track.

VIPER - Strikingly Fast Site Activation Software